Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioVascular Inc.

www.biovascularinc.com

Latest From Helsinn Birex Pharmaceuticals Ltd.

Pulled From EU Assessment Process: Orphan Drugs For Kidney Disease, Mesothelioma

Two orphan medicines have been withdrawn from the evaluation process at the European Medicines Agency, one of them for recurrent nephrotic syndrome, the other for mesothelioma. Three products are undergoing a re-evaluation after an initial negative opinion from the CHMP.

Drug Review Europe

Eisai’s Lenvima Gets CHMP Backing, Nexavar Marketing Rivalry Looms

Other medicines receiving positive opinions from the EU’s top scientific advisory panel after its March meeting include Helsinn’s Akynzeo for chemotherapy associated nausea and vomiting, the first 9-valent HPV vaccine, Sanofi Pasteur MSD’s Gardasil 9, and Boehringer Ingelheim’s Synjardy combination of empagliflozin and metformin.

BioPharmaceutical Europe

Supplement Firms Develop Health Care Provider Channel

The market for supplements sold by health care providers heats up, with firms offering practitioner-focused labeling, custom brands and products targeted to specific patient needs. As supplement use grows, more practitioners are interested in guiding patients’ choices in vitamins and other nutritionals.

Consumer North America

Deals Shaping the Medical Industry (07/2010)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • BioVascular Inc.
  • Senior Management
  • John Parrish, CEO
    Alison J Pilgrim, MD, PhD, CMO, VP, Clin. Dev.
    Eric Karpinski, VP, Bus. Dev.
  • Contact Info
  • BioVascular Inc.
    Phone: (858) 455-5000
    12230 El Camino Real
    Ste. 100
    San Diego, CA 92130
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register